AZD0780 + ezetimibe + rosuvastatin

AZD0780 + ezetimibe + rosuvastatin is a hypothetical or investigational oral combination therapy consisting of AZD0780, ezetimibe, and rosuvastatin, designed for the treatment of hypercholesterolemia and to lower low-density lipoprotein cholesterol (LDL-C) in patients at risk for atherosclerotic cardiovascular disease (ASCVD). - **AZD0780** is a novel, oral, small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor developed by AstraZeneca, which reduces circulating LDL-C by increasing LDL receptor recycling and hepatic uptake of LDL. It is currently in phase 3 trials as monotherapy adjunct to maximally tolerated statins[1][3][4][5]. - **Ezetimibe** is a cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, lowering cholesterol absorption and downstream plasma LDL-C. - **Rosuvastatin** is an HMG-CoA reductase inhibitor (statin) which reduces cholesterol synthesis in the liver, upregulating LDL receptor expression and lowering LDL-C. This combination would target three complementary pathways in cholesterol metabolism for potent LDL-C lowering and cardiovascular risk reduction. There is no specific evidence that a fixed-dose combination product containing all three agents has entered clinical trials or is approved, but all drugs are individually or in dual combinations studied for cardiovascular risk.